PURE Bioscience Announces Distribution Agreement with Pure Green, LLC for SDC-Based Disinfectant Pure Green, LLC Launches PureGreen24 – A Powerful Weapon Against MRSA SAN DIEGO, EPA registered PureGreen24 provides broad-spectrum protection against bacteria, including MRSA, viruses and fungi and provides 24-hour residual protection against Staph, Pseudomonas and Salmonella. PureGreen24 contains no ingredients categorized as “hazardous” by OSHA and meets school system and office building “green” standards. David L. Stetson, co-founder of Pure Green, LLC, commented, “We believe that the SDC antimicrobial technology is superior to any other disinfecting product available and is an ideal solution to the growing Staph and MRSA threats currently faced by the general public and our school systems nationwide. PureGreen24 is EPA registered for uses ranging from hospitals and medical clinics to mothers at home spraying PureGreen24 on children’s toys.” Stetson continued, “We are rapidly developing PureGreen24 distribution partner relationships throughout the Michael L. Krall, President and CEO of PURE Bioscience, added, “Given the accelerating need for effective antibacterial products that fight the spread of MRSA and other dangerous pathogens, we continue to actively expand our distribution channels through partners like Pure Green, LLC. We believe Pure Green’s commitment to improving human health and the environment, along with its aggressive marketing strategy and cutting-edge computerized customer service and distribution management systems, will help our SDC technology reach new, untapped markets, and will further strengthen the market positioning of our unique platform technology in the hard surface disinfectant segment.” PureGreen24 is available for sale nationwide. Prior to launching an SDC-based disinfectant, PURE’s private label distributors’ products must be sub-registered by PURE with the US Environmental Protection Agency (EPA) and each distributor must subsequently apply to all 50 states for individual state regulatory approval – a process that can take up to six months. About Pure Green, LLC Pure Green, LLC, About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE’s flagship technology, silver dihydrogen citrate (SDC), is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy, reduced toxicity and the inability of bacteria to become resistant to it. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products. PURE Bioscience, headquartered in This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.